LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

LLY

732.4

+0.01%↑

JNJ

177.02

+0.87%↑

ABBV

210.3

+1.16%↑

UNH

309.45

+2.3%↑

AZN

79.89

-0.16%↓

Search

Day One Biopharmaceuticals Inc

Fermé

SecteurSoins de santé

7.49 -1.58

Résumé

Variation du prix de l'action

24h

Actuel

Min

7.43

Max

7.5

Chiffres clés

By Trading Economics

Revenu

5.7M

-30M

Ventes

3.1M

34M

Marge bénéficiaire

-89.424

Employés

182

EBITDA

5.2M

-35M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

+206.26% upside

Dividendes

By Dow Jones

Prochains Résultats

29 oct. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

55M

738M

Ouverture précédente

9.07

Clôture précédente

7.49

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Day One Biopharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

29 août 2025, 18:43 UTC

Principaux Mouvements du Marché

Privia Health Shares Advance on Outlook Bump From Medicare Savings

29 août 2025, 15:07 UTC

Acquisitions, Fusions, Rachats

Strathcona Resources to Increase Minority Stake in MEG Energy, Vote Against Cenovus Buyout Plan

30 août 2025, 08:20 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

29 août 2025, 20:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

29 août 2025, 20:24 UTC

Résultats

Earnings Season Highlights on Tariffs, Consumer Spending, and More -- Barrons.com

29 août 2025, 20:17 UTC

Résultats

These Stocks Moved the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 19:18 UTC

Market Talk

Oil Futures End Week With Modest Gains -- Market Talk

29 août 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

29 août 2025, 18:36 UTC

Résultats

These Were the Best & Worst S&P 500 Stocks in August -- Barrons.com

29 août 2025, 18:26 UTC

Résultats

What the Stock Market Learned About Earnings and Consumers This Summer -- Barrons.com

29 août 2025, 17:48 UTC

Market Talk

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

29 août 2025, 17:10 UTC

Market Talk
Acquisitions, Fusions, Rachats

Regulator Firing Clears Path for Union Pacific-Norfolk Southern Deal -- Market Talk

29 août 2025, 16:57 UTC

Résultats

These Stocks Are Moving the Most Today: Alibaba, Marvell, Affirm, Nvidia, Dell, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 16:30 UTC

Acquisitions, Fusions, Rachats

Celsius Stock Is Spiking After PepsiCo Increases Stake -- Barrons.com

29 août 2025, 16:28 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Intended to Maintain Equivalent Economic Terms of Offer Following Dividend Payments by Sabadell

29 août 2025, 16:27 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Outlined in Announcement on May 9, 2024

29 août 2025, 16:26 UTC

Acquisitions, Fusions, Rachats

BBVA Now Offering 1 Newly Issued Ordinary BBVA Share and EUR0.70 in Cash for Every 5.5483 Ordinary Shares of Sabadell

29 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

BBVA: Adjustment Factors in Interim Dividend Paid by Sabadell to Its Shareholders

29 août 2025, 16:24 UTC

Acquisitions, Fusions, Rachats

BBVA Adjusts Offer for Banco de Sabadell

29 août 2025, 16:23 UTC

Market Talk
Acquisitions, Fusions, Rachats

Strathcona's Power Play in MEG Energy Jeopardizes Cenovus Deal -- Market Talk

29 août 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

29 août 2025, 16:06 UTC

Market Talk

Gold Futures Gain as U.S. Inflation Data Boost Rate Cut Hopes -- Market Talk

29 août 2025, 15:12 UTC

Market Talk
Résultats

Best Buy Surprise Comp Growth Potentially Driven by Switch 2 -- Market Talk

29 août 2025, 15:09 UTC

Résultats

Small-Cap Stocks Are Rallying Again. This Time It's Real. -- Barrons.com

29 août 2025, 15:01 UTC

Market Talk

Canadian Economy Expected to Slow But Grow in 2H -- Market Talk

29 août 2025, 14:49 UTC

Résultats

These Stocks Are Moving the Most Today: Marvell, Dell, Nvidia, Alibaba, Affirm, Autodesk, Ambarella, IREN, and More -- Barrons.com

29 août 2025, 14:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

29 août 2025, 14:49 UTC

Market Talk

Canada May Avoid Contraction in 3Q, But Is Expected to Struggle -- Market Talk

29 août 2025, 14:48 UTC

Résultats

Marvell Stock Tumbles. Why the AI Chip Player Keeps Disappointing the Market. -- Barrons.com

29 août 2025, 14:43 UTC

Market Talk

Rise in Canadian Household Spending May Not Worry Central Bank -- Market Talk

Comparaison

Variation de prix

Day One Biopharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

206.26% hausse

Prévisions sur 12 Mois

Moyen 23 USD  206.26%

Haut 34 USD

Bas 16 USD

Basé sur 9 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

9 ratings

8

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

6.26 / 7.47Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Bearish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Day One Biopharmaceuticals Inc

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.